cd45 1 pe cy7 Search Results


cd45 1 pe cy7  (Thermo Fisher)
96
Thermo Fisher cd45 1 pe cy7
Cd45 1 Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45 1 pe cy7/product/Thermo Fisher
Average 96 stars, based on 1 article reviews
cd45 1 pe cy7 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
pe-cy7-labelled anti-cd45.1  (Thermo Fisher)
90
Thermo Fisher pe-cy7-labelled anti-cd45.1
( a ) Representative contour plots and eosinophil <t>(CD45</t> + SiglecF + ) quantification in the ankle joint of WT mice with or without N. brasiliensis (Nb) challenge at day 9 post serum transfer ( n =5 per group). Numbers represent percentage in CD45 + cells. Frequency of eosinophils in the joints of WT mice with or without Nb challenge at the indicated time points ( n =5 per group). ( b ) Representative contour plots and percentage of neutrophil (CD45 + CD11b + Ly6G hi ) in the joints of WT mice with or without Nb challenge at day 9 post serum transfer ( n =5 per group). ( c ) Gating strategy for the identification of macrophages in the joints of WT mice. Percentage of total macrophages (defined as CD45 + Ly6G − SiglecF − CD11b hi F4/80 hi cells) in WT mice with or without Nb challenge 9 day post serum transfer ( n =5 per group). Numbers represent percentage of the parent population. ( d ) Frequency of pro (MHC II + ) and anti-inflammatory (MHC II − ) macrophages in the joints of WT mice with or without Nb challenge at the indicated time points ( n =15 per group). ( e , f ) Quantitative reverse transcriptase–PCR (RT–PCR) analyses of ( e ) Nos2 (encoding inducible nitric oxide synthase), Itgax (encoding CD11c) and Tnf , as well as ( f ) Arg1 (encoding arginase-1), Retnla (encoding resistin-like alpha), Chil3 (encoding chitinase-like protein 3), Mrc1 (encoding macrophage mannose receptor 1) and Il10 expression in synovial extracts from WT mice with or without Nb challenge ( n =6–10 per group). Data are shown as mean±s.e.m. Pictures are representative of 3 independent experiments, except for ( d ) where the data were pooled from three independent repeats. Asterisks mark statistically significant difference (* P <0.05, ** P <0.01 and *** P <0.001, determined by Student's t -test).
Pe Cy7 Labelled Anti Cd45.1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe-cy7-labelled anti-cd45.1/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
pe-cy7-labelled anti-cd45.1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
pe cy7 anti cd45  (Thermo Fisher)
86
Thermo Fisher pe cy7 anti cd45
Treatment with XPro1595 improves functional outcome in MOG-induced EAE. (A) Clinical course of MOG(35–55)-induced EAE in mice treated with vehicle (saline), etanercept or XPro1595. Treatment with pharmacological agents was initiated at Day 16, when at least half of the animals reached a minimum clinical score of 2. Both etanercept and XPro1595 were administered at a dose of 10 mg/kg every 3 days until the end of the experiment (55 days post-induction). Results are expressed as the daily mean clinical score ± SEM of 13–15 animals/group from two independent experiments. The XPro1595 curve is significantly different from both vehicle and etanercept curves (P < 0.0001, Mann–Whitney test). (B) Flow cytometry analysis of microglia (CD45lowCD11b+ population, black dots) and infiltrating macrophages (CD45highCD11b+ population, red dots) in the spinal cord of vehicle-, etanercept- and XPro1595-treated mice at acute disease (28 days post-induction). A representative experiment is shown, obtained by sampling eight animals per group. (C) Double immunostaining for <t>CD45</t> (green) and GFAP (red) in the thoracic spinal cord of vehicle-, etanercept- and XPro1595-treated mice at chronic disease (55 days post-induction); scale bar = 100 µm. (D) Quantification of CD45 and GFAP protein expression in spinal cord tissue of vehicle-, etanercept- and XPro1595-treated mice at 55 days post-induction. Data are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein expression. Representative experiments are shown. Results, expressed as per cent of vehicle, are the mean ± SEM of five animals per group. *P < 0.05 versus vehicle and etanercept; **P < 0.05 versus vehicle by one-way ANOVA with Tukey's test.
Pe Cy7 Anti Cd45, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe cy7 anti cd45/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
pe cy7 anti cd45 - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier
anti-cd45.1 pe-cy7  (Becton Dickinson)
90
Becton Dickinson anti-cd45.1 pe-cy7
Treatment with XPro1595 improves functional outcome in MOG-induced EAE. (A) Clinical course of MOG(35–55)-induced EAE in mice treated with vehicle (saline), etanercept or XPro1595. Treatment with pharmacological agents was initiated at Day 16, when at least half of the animals reached a minimum clinical score of 2. Both etanercept and XPro1595 were administered at a dose of 10 mg/kg every 3 days until the end of the experiment (55 days post-induction). Results are expressed as the daily mean clinical score ± SEM of 13–15 animals/group from two independent experiments. The XPro1595 curve is significantly different from both vehicle and etanercept curves (P < 0.0001, Mann–Whitney test). (B) Flow cytometry analysis of microglia (CD45lowCD11b+ population, black dots) and infiltrating macrophages (CD45highCD11b+ population, red dots) in the spinal cord of vehicle-, etanercept- and XPro1595-treated mice at acute disease (28 days post-induction). A representative experiment is shown, obtained by sampling eight animals per group. (C) Double immunostaining for <t>CD45</t> (green) and GFAP (red) in the thoracic spinal cord of vehicle-, etanercept- and XPro1595-treated mice at chronic disease (55 days post-induction); scale bar = 100 µm. (D) Quantification of CD45 and GFAP protein expression in spinal cord tissue of vehicle-, etanercept- and XPro1595-treated mice at 55 days post-induction. Data are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein expression. Representative experiments are shown. Results, expressed as per cent of vehicle, are the mean ± SEM of five animals per group. *P < 0.05 versus vehicle and etanercept; **P < 0.05 versus vehicle by one-way ANOVA with Tukey's test.
Anti Cd45.1 Pe Cy7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd45.1 pe-cy7/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-cd45.1 pe-cy7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
ter 119  (Thermo Fisher)
86
Thermo Fisher ter 119
Treatment with XPro1595 improves functional outcome in MOG-induced EAE. (A) Clinical course of MOG(35–55)-induced EAE in mice treated with vehicle (saline), etanercept or XPro1595. Treatment with pharmacological agents was initiated at Day 16, when at least half of the animals reached a minimum clinical score of 2. Both etanercept and XPro1595 were administered at a dose of 10 mg/kg every 3 days until the end of the experiment (55 days post-induction). Results are expressed as the daily mean clinical score ± SEM of 13–15 animals/group from two independent experiments. The XPro1595 curve is significantly different from both vehicle and etanercept curves (P < 0.0001, Mann–Whitney test). (B) Flow cytometry analysis of microglia (CD45lowCD11b+ population, black dots) and infiltrating macrophages (CD45highCD11b+ population, red dots) in the spinal cord of vehicle-, etanercept- and XPro1595-treated mice at acute disease (28 days post-induction). A representative experiment is shown, obtained by sampling eight animals per group. (C) Double immunostaining for <t>CD45</t> (green) and GFAP (red) in the thoracic spinal cord of vehicle-, etanercept- and XPro1595-treated mice at chronic disease (55 days post-induction); scale bar = 100 µm. (D) Quantification of CD45 and GFAP protein expression in spinal cord tissue of vehicle-, etanercept- and XPro1595-treated mice at 55 days post-induction. Data are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein expression. Representative experiments are shown. Results, expressed as per cent of vehicle, are the mean ± SEM of five animals per group. *P < 0.05 versus vehicle and etanercept; **P < 0.05 versus vehicle by one-way ANOVA with Tukey's test.
Ter 119, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ter 119/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
ter 119 - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier
anti-mouse cd45.1 pe-cy7  (Thermo Fisher)
90
Thermo Fisher anti-mouse cd45.1 pe-cy7
Treatment with XPro1595 improves functional outcome in MOG-induced EAE. (A) Clinical course of MOG(35–55)-induced EAE in mice treated with vehicle (saline), etanercept or XPro1595. Treatment with pharmacological agents was initiated at Day 16, when at least half of the animals reached a minimum clinical score of 2. Both etanercept and XPro1595 were administered at a dose of 10 mg/kg every 3 days until the end of the experiment (55 days post-induction). Results are expressed as the daily mean clinical score ± SEM of 13–15 animals/group from two independent experiments. The XPro1595 curve is significantly different from both vehicle and etanercept curves (P < 0.0001, Mann–Whitney test). (B) Flow cytometry analysis of microglia (CD45lowCD11b+ population, black dots) and infiltrating macrophages (CD45highCD11b+ population, red dots) in the spinal cord of vehicle-, etanercept- and XPro1595-treated mice at acute disease (28 days post-induction). A representative experiment is shown, obtained by sampling eight animals per group. (C) Double immunostaining for <t>CD45</t> (green) and GFAP (red) in the thoracic spinal cord of vehicle-, etanercept- and XPro1595-treated mice at chronic disease (55 days post-induction); scale bar = 100 µm. (D) Quantification of CD45 and GFAP protein expression in spinal cord tissue of vehicle-, etanercept- and XPro1595-treated mice at 55 days post-induction. Data are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein expression. Representative experiments are shown. Results, expressed as per cent of vehicle, are the mean ± SEM of five animals per group. *P < 0.05 versus vehicle and etanercept; **P < 0.05 versus vehicle by one-way ANOVA with Tukey's test.
Anti Mouse Cd45.1 Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mouse cd45.1 pe-cy7/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-mouse cd45.1 pe-cy7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd45.1 pe-cy7 antibody  (Thermo Fisher)
90
Thermo Fisher cd45.1 pe-cy7 antibody
Treatment with XPro1595 improves functional outcome in MOG-induced EAE. (A) Clinical course of MOG(35–55)-induced EAE in mice treated with vehicle (saline), etanercept or XPro1595. Treatment with pharmacological agents was initiated at Day 16, when at least half of the animals reached a minimum clinical score of 2. Both etanercept and XPro1595 were administered at a dose of 10 mg/kg every 3 days until the end of the experiment (55 days post-induction). Results are expressed as the daily mean clinical score ± SEM of 13–15 animals/group from two independent experiments. The XPro1595 curve is significantly different from both vehicle and etanercept curves (P < 0.0001, Mann–Whitney test). (B) Flow cytometry analysis of microglia (CD45lowCD11b+ population, black dots) and infiltrating macrophages (CD45highCD11b+ population, red dots) in the spinal cord of vehicle-, etanercept- and XPro1595-treated mice at acute disease (28 days post-induction). A representative experiment is shown, obtained by sampling eight animals per group. (C) Double immunostaining for <t>CD45</t> (green) and GFAP (red) in the thoracic spinal cord of vehicle-, etanercept- and XPro1595-treated mice at chronic disease (55 days post-induction); scale bar = 100 µm. (D) Quantification of CD45 and GFAP protein expression in spinal cord tissue of vehicle-, etanercept- and XPro1595-treated mice at 55 days post-induction. Data are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein expression. Representative experiments are shown. Results, expressed as per cent of vehicle, are the mean ± SEM of five animals per group. *P < 0.05 versus vehicle and etanercept; **P < 0.05 versus vehicle by one-way ANOVA with Tukey's test.
Cd45.1 Pe Cy7 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45.1 pe-cy7 antibody/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
cd45.1 pe-cy7 antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd45 1 pe cy7 tonbo biosciences a20  (Cytek Biosciences)
93
Cytek Biosciences cd45 1 pe cy7 tonbo biosciences a20
Treatment with XPro1595 improves functional outcome in MOG-induced EAE. (A) Clinical course of MOG(35–55)-induced EAE in mice treated with vehicle (saline), etanercept or XPro1595. Treatment with pharmacological agents was initiated at Day 16, when at least half of the animals reached a minimum clinical score of 2. Both etanercept and XPro1595 were administered at a dose of 10 mg/kg every 3 days until the end of the experiment (55 days post-induction). Results are expressed as the daily mean clinical score ± SEM of 13–15 animals/group from two independent experiments. The XPro1595 curve is significantly different from both vehicle and etanercept curves (P < 0.0001, Mann–Whitney test). (B) Flow cytometry analysis of microglia (CD45lowCD11b+ population, black dots) and infiltrating macrophages (CD45highCD11b+ population, red dots) in the spinal cord of vehicle-, etanercept- and XPro1595-treated mice at acute disease (28 days post-induction). A representative experiment is shown, obtained by sampling eight animals per group. (C) Double immunostaining for <t>CD45</t> (green) and GFAP (red) in the thoracic spinal cord of vehicle-, etanercept- and XPro1595-treated mice at chronic disease (55 days post-induction); scale bar = 100 µm. (D) Quantification of CD45 and GFAP protein expression in spinal cord tissue of vehicle-, etanercept- and XPro1595-treated mice at 55 days post-induction. Data are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein expression. Representative experiments are shown. Results, expressed as per cent of vehicle, are the mean ± SEM of five animals per group. *P < 0.05 versus vehicle and etanercept; **P < 0.05 versus vehicle by one-way ANOVA with Tukey's test.
Cd45 1 Pe Cy7 Tonbo Biosciences A20, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45 1 pe cy7 tonbo biosciences a20/product/Cytek Biosciences
Average 93 stars, based on 1 article reviews
cd45 1 pe cy7 tonbo biosciences a20 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
fitc anti-mouse cd34 antibody, ram34  (Thermo Fisher)
90
Thermo Fisher fitc anti-mouse cd34 antibody, ram34
Example bone marrow engraftment antibody stain for 10 million whole bone marrow cells
Fitc Anti Mouse Cd34 Antibody, Ram34, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fitc anti-mouse cd34 antibody, ram34/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
fitc anti-mouse cd34 antibody, ram34 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd45.1-pe-cy7  (Thermo Fisher)
90
Thermo Fisher cd45.1-pe-cy7
Example bone marrow engraftment antibody stain for 10 million whole bone marrow cells
Cd45.1 Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45.1-pe-cy7/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
cd45.1-pe-cy7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd45  (Thermo Fisher)
86
Thermo Fisher cd45
Example bone marrow engraftment antibody stain for 10 million whole bone marrow cells
Cd45, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
cd45 - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier

Image Search Results


( a ) Representative contour plots and eosinophil (CD45 + SiglecF + ) quantification in the ankle joint of WT mice with or without N. brasiliensis (Nb) challenge at day 9 post serum transfer ( n =5 per group). Numbers represent percentage in CD45 + cells. Frequency of eosinophils in the joints of WT mice with or without Nb challenge at the indicated time points ( n =5 per group). ( b ) Representative contour plots and percentage of neutrophil (CD45 + CD11b + Ly6G hi ) in the joints of WT mice with or without Nb challenge at day 9 post serum transfer ( n =5 per group). ( c ) Gating strategy for the identification of macrophages in the joints of WT mice. Percentage of total macrophages (defined as CD45 + Ly6G − SiglecF − CD11b hi F4/80 hi cells) in WT mice with or without Nb challenge 9 day post serum transfer ( n =5 per group). Numbers represent percentage of the parent population. ( d ) Frequency of pro (MHC II + ) and anti-inflammatory (MHC II − ) macrophages in the joints of WT mice with or without Nb challenge at the indicated time points ( n =15 per group). ( e , f ) Quantitative reverse transcriptase–PCR (RT–PCR) analyses of ( e ) Nos2 (encoding inducible nitric oxide synthase), Itgax (encoding CD11c) and Tnf , as well as ( f ) Arg1 (encoding arginase-1), Retnla (encoding resistin-like alpha), Chil3 (encoding chitinase-like protein 3), Mrc1 (encoding macrophage mannose receptor 1) and Il10 expression in synovial extracts from WT mice with or without Nb challenge ( n =6–10 per group). Data are shown as mean±s.e.m. Pictures are representative of 3 independent experiments, except for ( d ) where the data were pooled from three independent repeats. Asterisks mark statistically significant difference (* P <0.05, ** P <0.01 and *** P <0.001, determined by Student's t -test).

Journal: Nature Communications

Article Title: Th2 and eosinophil responses suppress inflammatory arthritis

doi: 10.1038/ncomms11596

Figure Lengend Snippet: ( a ) Representative contour plots and eosinophil (CD45 + SiglecF + ) quantification in the ankle joint of WT mice with or without N. brasiliensis (Nb) challenge at day 9 post serum transfer ( n =5 per group). Numbers represent percentage in CD45 + cells. Frequency of eosinophils in the joints of WT mice with or without Nb challenge at the indicated time points ( n =5 per group). ( b ) Representative contour plots and percentage of neutrophil (CD45 + CD11b + Ly6G hi ) in the joints of WT mice with or without Nb challenge at day 9 post serum transfer ( n =5 per group). ( c ) Gating strategy for the identification of macrophages in the joints of WT mice. Percentage of total macrophages (defined as CD45 + Ly6G − SiglecF − CD11b hi F4/80 hi cells) in WT mice with or without Nb challenge 9 day post serum transfer ( n =5 per group). Numbers represent percentage of the parent population. ( d ) Frequency of pro (MHC II + ) and anti-inflammatory (MHC II − ) macrophages in the joints of WT mice with or without Nb challenge at the indicated time points ( n =15 per group). ( e , f ) Quantitative reverse transcriptase–PCR (RT–PCR) analyses of ( e ) Nos2 (encoding inducible nitric oxide synthase), Itgax (encoding CD11c) and Tnf , as well as ( f ) Arg1 (encoding arginase-1), Retnla (encoding resistin-like alpha), Chil3 (encoding chitinase-like protein 3), Mrc1 (encoding macrophage mannose receptor 1) and Il10 expression in synovial extracts from WT mice with or without Nb challenge ( n =6–10 per group). Data are shown as mean±s.e.m. Pictures are representative of 3 independent experiments, except for ( d ) where the data were pooled from three independent repeats. Asterisks mark statistically significant difference (* P <0.05, ** P <0.01 and *** P <0.001, determined by Student's t -test).

Article Snippet: After 6 weeks, chimerism was verified by flow cytometry for the appropriate CD45 allele (PE-Cy7-labelled anti-CD45.1 and AlexaFluo700- labelled anti-CD45.2; 1:400; eBioscience).

Techniques: Reverse Transcription, Reverse Transcription Polymerase Chain Reaction, Expressing

( a ) Arthritis score in WT unchallenged and N. brasiliensis (Nb) challenged WT mice and eosinophil-deficient ΔdblGATA mice induced for K/BxN serum transfer arthritis ( n =6 per group). ( b ) Haematoxylin/eosin (H&E) and tartrate-resistant acid phosphatase (TRAP) staining and quantification of inflammation area, erosion area and number of osteoclasts (Oc.N) per paw 9 days after serum transfer ( n =6 per group); scale bar, 500 μm. ( c ) Arthritis score in WT and ΔdblGATA mice after K/BxN serum transfer ( n =6 per group). ( d ) Arthritis scores in WT mice injected with vehicle or recombinant IL-5 during serum transfer ( n =4 per group). ( e ) Arthritis scores in WT and IL-5tg mice after serum transfer ( n =6 per group). ( f ) H&E and TRAP staining and ( g ) quantification of inflammation area, erosion area and N.Oc per paw 9 days after serum transfer ( n =6 per group); scale bar, 500 μm. ( h ) Analyses of Il6, Il1β and Tnfα mRNA expression in synovial extracts and IL6, IL1β and TNFα serum level of WT and ΔdblGATA mice 9 days after serum transfer ( n =6 per group). ( i ) Percentage of CD45 + CD11b + Ly6G hi neutrophils in the joints of arthritic WT and ΔdblGATA mice ( n =5 per group). ( j ) Percentage of peripheral CD11b + Ly6C hi monocytes in arthritic WT and ΔdblGATA mice ( n =3 per group). All analyses above were performed 9 days after serum transfer. ( k ) Percentage of total macrophages (CD45 + Ly6G − SiglecF − CD11b hi F4/80 hi cells), MHC II + macrophages and MHC II − macrophages in the joints of WT and ΔdblGATA mice 9 day after serum transfer ( n =5 per group). ( l ) Quantitative reverse transcriptase–PCR (RT–PCR) analyses of Nos2 and Itgax expression in joint extracts of WT and ΔdblGATA arthritic mice ( n =6 per group). ( m ) Quantitative RT–PCR analyses of Arg1 , Retnla , Chil3 and Mrc1 expression in joint extracts of WT and ΔdblGATA mice 9 days after serum transfer ( n =6–11 per group). Data are expressed as mean±s.e.m. Pictures are representative of 3 independent experiments. Asterisks mark statistically significant difference (* P <0.05, ** P <0.01 and *** P <0.001 determined by Student's t -test for single comparison).

Journal: Nature Communications

Article Title: Th2 and eosinophil responses suppress inflammatory arthritis

doi: 10.1038/ncomms11596

Figure Lengend Snippet: ( a ) Arthritis score in WT unchallenged and N. brasiliensis (Nb) challenged WT mice and eosinophil-deficient ΔdblGATA mice induced for K/BxN serum transfer arthritis ( n =6 per group). ( b ) Haematoxylin/eosin (H&E) and tartrate-resistant acid phosphatase (TRAP) staining and quantification of inflammation area, erosion area and number of osteoclasts (Oc.N) per paw 9 days after serum transfer ( n =6 per group); scale bar, 500 μm. ( c ) Arthritis score in WT and ΔdblGATA mice after K/BxN serum transfer ( n =6 per group). ( d ) Arthritis scores in WT mice injected with vehicle or recombinant IL-5 during serum transfer ( n =4 per group). ( e ) Arthritis scores in WT and IL-5tg mice after serum transfer ( n =6 per group). ( f ) H&E and TRAP staining and ( g ) quantification of inflammation area, erosion area and N.Oc per paw 9 days after serum transfer ( n =6 per group); scale bar, 500 μm. ( h ) Analyses of Il6, Il1β and Tnfα mRNA expression in synovial extracts and IL6, IL1β and TNFα serum level of WT and ΔdblGATA mice 9 days after serum transfer ( n =6 per group). ( i ) Percentage of CD45 + CD11b + Ly6G hi neutrophils in the joints of arthritic WT and ΔdblGATA mice ( n =5 per group). ( j ) Percentage of peripheral CD11b + Ly6C hi monocytes in arthritic WT and ΔdblGATA mice ( n =3 per group). All analyses above were performed 9 days after serum transfer. ( k ) Percentage of total macrophages (CD45 + Ly6G − SiglecF − CD11b hi F4/80 hi cells), MHC II + macrophages and MHC II − macrophages in the joints of WT and ΔdblGATA mice 9 day after serum transfer ( n =5 per group). ( l ) Quantitative reverse transcriptase–PCR (RT–PCR) analyses of Nos2 and Itgax expression in joint extracts of WT and ΔdblGATA arthritic mice ( n =6 per group). ( m ) Quantitative RT–PCR analyses of Arg1 , Retnla , Chil3 and Mrc1 expression in joint extracts of WT and ΔdblGATA mice 9 days after serum transfer ( n =6–11 per group). Data are expressed as mean±s.e.m. Pictures are representative of 3 independent experiments. Asterisks mark statistically significant difference (* P <0.05, ** P <0.01 and *** P <0.001 determined by Student's t -test for single comparison).

Article Snippet: After 6 weeks, chimerism was verified by flow cytometry for the appropriate CD45 allele (PE-Cy7-labelled anti-CD45.1 and AlexaFluo700- labelled anti-CD45.2; 1:400; eBioscience).

Techniques: Staining, Injection, Recombinant, Expressing, Reverse Transcription, Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Comparison

Treatment with XPro1595 improves functional outcome in MOG-induced EAE. (A) Clinical course of MOG(35–55)-induced EAE in mice treated with vehicle (saline), etanercept or XPro1595. Treatment with pharmacological agents was initiated at Day 16, when at least half of the animals reached a minimum clinical score of 2. Both etanercept and XPro1595 were administered at a dose of 10 mg/kg every 3 days until the end of the experiment (55 days post-induction). Results are expressed as the daily mean clinical score ± SEM of 13–15 animals/group from two independent experiments. The XPro1595 curve is significantly different from both vehicle and etanercept curves (P < 0.0001, Mann–Whitney test). (B) Flow cytometry analysis of microglia (CD45lowCD11b+ population, black dots) and infiltrating macrophages (CD45highCD11b+ population, red dots) in the spinal cord of vehicle-, etanercept- and XPro1595-treated mice at acute disease (28 days post-induction). A representative experiment is shown, obtained by sampling eight animals per group. (C) Double immunostaining for CD45 (green) and GFAP (red) in the thoracic spinal cord of vehicle-, etanercept- and XPro1595-treated mice at chronic disease (55 days post-induction); scale bar = 100 µm. (D) Quantification of CD45 and GFAP protein expression in spinal cord tissue of vehicle-, etanercept- and XPro1595-treated mice at 55 days post-induction. Data are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein expression. Representative experiments are shown. Results, expressed as per cent of vehicle, are the mean ± SEM of five animals per group. *P < 0.05 versus vehicle and etanercept; **P < 0.05 versus vehicle by one-way ANOVA with Tukey's test.

Journal: Brain

Article Title: Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination

doi: 10.1093/brain/awr199

Figure Lengend Snippet: Treatment with XPro1595 improves functional outcome in MOG-induced EAE. (A) Clinical course of MOG(35–55)-induced EAE in mice treated with vehicle (saline), etanercept or XPro1595. Treatment with pharmacological agents was initiated at Day 16, when at least half of the animals reached a minimum clinical score of 2. Both etanercept and XPro1595 were administered at a dose of 10 mg/kg every 3 days until the end of the experiment (55 days post-induction). Results are expressed as the daily mean clinical score ± SEM of 13–15 animals/group from two independent experiments. The XPro1595 curve is significantly different from both vehicle and etanercept curves (P < 0.0001, Mann–Whitney test). (B) Flow cytometry analysis of microglia (CD45lowCD11b+ population, black dots) and infiltrating macrophages (CD45highCD11b+ population, red dots) in the spinal cord of vehicle-, etanercept- and XPro1595-treated mice at acute disease (28 days post-induction). A representative experiment is shown, obtained by sampling eight animals per group. (C) Double immunostaining for CD45 (green) and GFAP (red) in the thoracic spinal cord of vehicle-, etanercept- and XPro1595-treated mice at chronic disease (55 days post-induction); scale bar = 100 µm. (D) Quantification of CD45 and GFAP protein expression in spinal cord tissue of vehicle-, etanercept- and XPro1595-treated mice at 55 days post-induction. Data are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein expression. Representative experiments are shown. Results, expressed as per cent of vehicle, are the mean ± SEM of five animals per group. *P < 0.05 versus vehicle and etanercept; **P < 0.05 versus vehicle by one-way ANOVA with Tukey's test.

Article Snippet: Cells were incubated on ice for 10 min with anti-CD16/32 (FcR block, eBioscience) to prevent non-specific staining and subsequently stained for 30 min at 4°C with: PE-Cy7-anti-CD45 (1:10 000); AlexaFluor488-anti-CD3, Pacific Blue- or PE-anti-CD4 (1:200); APC-anti-CD8 (1:200); APC-AlexaFluor750-anti-B220 (1:200); PE-anti-NK1.1 (1:200); and eFluor450-CD11b (1:200), from eBioscience.

Techniques: Functional Assay, MANN-WHITNEY, Flow Cytometry, Sampling, Double Immunostaining, Expressing

Flow cytometric analysis of leucocyte profiles in spleen and spinal cord of vehicle-, etanercept- and XPro1595-treated mice at 28 and 55 days post-induction

Journal: Brain

Article Title: Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination

doi: 10.1093/brain/awr199

Figure Lengend Snippet: Flow cytometric analysis of leucocyte profiles in spleen and spinal cord of vehicle-, etanercept- and XPro1595-treated mice at 28 and 55 days post-induction

Article Snippet: Cells were incubated on ice for 10 min with anti-CD16/32 (FcR block, eBioscience) to prevent non-specific staining and subsequently stained for 30 min at 4°C with: PE-Cy7-anti-CD45 (1:10 000); AlexaFluor488-anti-CD3, Pacific Blue- or PE-anti-CD4 (1:200); APC-anti-CD8 (1:200); APC-AlexaFluor750-anti-B220 (1:200); PE-anti-NK1.1 (1:200); and eFluor450-CD11b (1:200), from eBioscience.

Techniques:

Example bone marrow engraftment antibody stain for 10 million whole bone marrow cells

Journal: Nature protocols

Article Title: Long-term ex vivo expansion of mouse hematopoietic stem cells

doi: 10.1038/s41596-019-0263-2

Figure Lengend Snippet: Example bone marrow engraftment antibody stain for 10 million whole bone marrow cells

Article Snippet: FACS and flow cytometry reagents Biotin anti-mouse CD4 antibody, clone RM4–5 (eBioscience Cat# 13–0042-85, RRID:AB_466330) Biotin anti-mouse CD8 antibody, clone 53–6.7 (eBioscience Cat# 13–0081-86, RRID:AB_466348) Biotin anti-mouse CD45R/B220 antibody, clone RA3–6B2 (eBioscience Cat# 13–0452-85, RRID:AB_466450) Biotin anti-mouse TER-119 antibody, clone TER-119 (eBioscience Cat# 13–5921-85, RRID:AB_466798) Biotin anti-mouse Gr-1/Ly-6G antibody, clone RB6–8C5 (eBioscience Cat# 13–5931-85, RRID: AB_466801) Biotin anti-mouse CD127 antibody, clone A7R34 (eBioscience Cat# 13–1271-85, RRID: AB_466589) Biotin anti-mouse FceR1 antibody, clone MAR-1 (eBioscience Cat# 13–5898-82, RRID:AB_466783) APC/eFluor780 Streptavidin (eBioscience Cat# 47–4317-82, RRID: AB_10366688) APC anti-mouse c-Kit antibody, clone 2B8 (eBioscience Cat# 17–1171-83, RRID:AB_469431) PE anti-mouse Sca-1/Ly-6A/E antibody, clone D7 (BioLegend Cat# 122508, RRID: AB_756193) PE/Cy7 anti-mouse CD150 antibody, clone TC15–12F12.2 (Biolegend Cat# 115914, RRID: AB_439797) FITC anti-mouse CD34 antibody, clone RAM34 (eBioscience Cat# 11–0341-85, RRID: AB_465022) PE/Cy7 anti-mouse CD45.1 antibody, clone A20 (Biolegend Cat# 110730, AB_1134168; TONBO Biosciences Cat# 60–0453, RRID:AB_2621850) BrilliantViolet421 (BV421) anti-mouse CD45.2 antibody, clone 104 (Biolegend Cat# 109832, RRID:AB_2565511) or eFluor450 anti-mouse CD45.2 antibody, clone 104 (eBioscience Cat# 48–0454-82, RRID: AB_11042125) PE anti-mouse CD11b antibody, clone M1/M7 (eBiosciences Cat# 12–0112-82, RRID: AB_2734869) PE anti-mouse Gr1/Ly-6G antibody, clone RB6–8C5 (eBioscience Cat# 12–5931-82, RRID: AB_466045) APC anti-mouse CD4 antibody, clone RM4–5 (eBioscience Cat# 17–0042-83; RRID:AB_469324) APC anti-mouse CD8 antibody, clone 53–6.7 (eBioscience 17–0081-83.

Techniques: Staining

Example antibody stain for 10 million c-Kit-enriched bone marrow cells

Journal: Nature protocols

Article Title: Long-term ex vivo expansion of mouse hematopoietic stem cells

doi: 10.1038/s41596-019-0263-2

Figure Lengend Snippet: Example antibody stain for 10 million c-Kit-enriched bone marrow cells

Article Snippet: FACS and flow cytometry reagents Biotin anti-mouse CD4 antibody, clone RM4–5 (eBioscience Cat# 13–0042-85, RRID:AB_466330) Biotin anti-mouse CD8 antibody, clone 53–6.7 (eBioscience Cat# 13–0081-86, RRID:AB_466348) Biotin anti-mouse CD45R/B220 antibody, clone RA3–6B2 (eBioscience Cat# 13–0452-85, RRID:AB_466450) Biotin anti-mouse TER-119 antibody, clone TER-119 (eBioscience Cat# 13–5921-85, RRID:AB_466798) Biotin anti-mouse Gr-1/Ly-6G antibody, clone RB6–8C5 (eBioscience Cat# 13–5931-85, RRID: AB_466801) Biotin anti-mouse CD127 antibody, clone A7R34 (eBioscience Cat# 13–1271-85, RRID: AB_466589) Biotin anti-mouse FceR1 antibody, clone MAR-1 (eBioscience Cat# 13–5898-82, RRID:AB_466783) APC/eFluor780 Streptavidin (eBioscience Cat# 47–4317-82, RRID: AB_10366688) APC anti-mouse c-Kit antibody, clone 2B8 (eBioscience Cat# 17–1171-83, RRID:AB_469431) PE anti-mouse Sca-1/Ly-6A/E antibody, clone D7 (BioLegend Cat# 122508, RRID: AB_756193) PE/Cy7 anti-mouse CD150 antibody, clone TC15–12F12.2 (Biolegend Cat# 115914, RRID: AB_439797) FITC anti-mouse CD34 antibody, clone RAM34 (eBioscience Cat# 11–0341-85, RRID: AB_465022) PE/Cy7 anti-mouse CD45.1 antibody, clone A20 (Biolegend Cat# 110730, AB_1134168; TONBO Biosciences Cat# 60–0453, RRID:AB_2621850) BrilliantViolet421 (BV421) anti-mouse CD45.2 antibody, clone 104 (Biolegend Cat# 109832, RRID:AB_2565511) or eFluor450 anti-mouse CD45.2 antibody, clone 104 (eBioscience Cat# 48–0454-82, RRID: AB_11042125) PE anti-mouse CD11b antibody, clone M1/M7 (eBiosciences Cat# 12–0112-82, RRID: AB_2734869) PE anti-mouse Gr1/Ly-6G antibody, clone RB6–8C5 (eBioscience Cat# 12–5931-82, RRID: AB_466045) APC anti-mouse CD4 antibody, clone RM4–5 (eBioscience Cat# 17–0042-83; RRID:AB_469324) APC anti-mouse CD8 antibody, clone 53–6.7 (eBioscience 17–0081-83.

Techniques: Staining

Example cultured HSC antibody stain for 10 samples ( <50,000 cell/sample)

Journal: Nature protocols

Article Title: Long-term ex vivo expansion of mouse hematopoietic stem cells

doi: 10.1038/s41596-019-0263-2

Figure Lengend Snippet: Example cultured HSC antibody stain for 10 samples ( <50,000 cell/sample)

Article Snippet: FACS and flow cytometry reagents Biotin anti-mouse CD4 antibody, clone RM4–5 (eBioscience Cat# 13–0042-85, RRID:AB_466330) Biotin anti-mouse CD8 antibody, clone 53–6.7 (eBioscience Cat# 13–0081-86, RRID:AB_466348) Biotin anti-mouse CD45R/B220 antibody, clone RA3–6B2 (eBioscience Cat# 13–0452-85, RRID:AB_466450) Biotin anti-mouse TER-119 antibody, clone TER-119 (eBioscience Cat# 13–5921-85, RRID:AB_466798) Biotin anti-mouse Gr-1/Ly-6G antibody, clone RB6–8C5 (eBioscience Cat# 13–5931-85, RRID: AB_466801) Biotin anti-mouse CD127 antibody, clone A7R34 (eBioscience Cat# 13–1271-85, RRID: AB_466589) Biotin anti-mouse FceR1 antibody, clone MAR-1 (eBioscience Cat# 13–5898-82, RRID:AB_466783) APC/eFluor780 Streptavidin (eBioscience Cat# 47–4317-82, RRID: AB_10366688) APC anti-mouse c-Kit antibody, clone 2B8 (eBioscience Cat# 17–1171-83, RRID:AB_469431) PE anti-mouse Sca-1/Ly-6A/E antibody, clone D7 (BioLegend Cat# 122508, RRID: AB_756193) PE/Cy7 anti-mouse CD150 antibody, clone TC15–12F12.2 (Biolegend Cat# 115914, RRID: AB_439797) FITC anti-mouse CD34 antibody, clone RAM34 (eBioscience Cat# 11–0341-85, RRID: AB_465022) PE/Cy7 anti-mouse CD45.1 antibody, clone A20 (Biolegend Cat# 110730, AB_1134168; TONBO Biosciences Cat# 60–0453, RRID:AB_2621850) BrilliantViolet421 (BV421) anti-mouse CD45.2 antibody, clone 104 (Biolegend Cat# 109832, RRID:AB_2565511) or eFluor450 anti-mouse CD45.2 antibody, clone 104 (eBioscience Cat# 48–0454-82, RRID: AB_11042125) PE anti-mouse CD11b antibody, clone M1/M7 (eBiosciences Cat# 12–0112-82, RRID: AB_2734869) PE anti-mouse Gr1/Ly-6G antibody, clone RB6–8C5 (eBioscience Cat# 12–5931-82, RRID: AB_466045) APC anti-mouse CD4 antibody, clone RM4–5 (eBioscience Cat# 17–0042-83; RRID:AB_469324) APC anti-mouse CD8 antibody, clone 53–6.7 (eBioscience 17–0081-83.

Techniques: Cell Culture, Staining

Example peripheral blood antibody stain for 20 samples

Journal: Nature protocols

Article Title: Long-term ex vivo expansion of mouse hematopoietic stem cells

doi: 10.1038/s41596-019-0263-2

Figure Lengend Snippet: Example peripheral blood antibody stain for 20 samples

Article Snippet: FACS and flow cytometry reagents Biotin anti-mouse CD4 antibody, clone RM4–5 (eBioscience Cat# 13–0042-85, RRID:AB_466330) Biotin anti-mouse CD8 antibody, clone 53–6.7 (eBioscience Cat# 13–0081-86, RRID:AB_466348) Biotin anti-mouse CD45R/B220 antibody, clone RA3–6B2 (eBioscience Cat# 13–0452-85, RRID:AB_466450) Biotin anti-mouse TER-119 antibody, clone TER-119 (eBioscience Cat# 13–5921-85, RRID:AB_466798) Biotin anti-mouse Gr-1/Ly-6G antibody, clone RB6–8C5 (eBioscience Cat# 13–5931-85, RRID: AB_466801) Biotin anti-mouse CD127 antibody, clone A7R34 (eBioscience Cat# 13–1271-85, RRID: AB_466589) Biotin anti-mouse FceR1 antibody, clone MAR-1 (eBioscience Cat# 13–5898-82, RRID:AB_466783) APC/eFluor780 Streptavidin (eBioscience Cat# 47–4317-82, RRID: AB_10366688) APC anti-mouse c-Kit antibody, clone 2B8 (eBioscience Cat# 17–1171-83, RRID:AB_469431) PE anti-mouse Sca-1/Ly-6A/E antibody, clone D7 (BioLegend Cat# 122508, RRID: AB_756193) PE/Cy7 anti-mouse CD150 antibody, clone TC15–12F12.2 (Biolegend Cat# 115914, RRID: AB_439797) FITC anti-mouse CD34 antibody, clone RAM34 (eBioscience Cat# 11–0341-85, RRID: AB_465022) PE/Cy7 anti-mouse CD45.1 antibody, clone A20 (Biolegend Cat# 110730, AB_1134168; TONBO Biosciences Cat# 60–0453, RRID:AB_2621850) BrilliantViolet421 (BV421) anti-mouse CD45.2 antibody, clone 104 (Biolegend Cat# 109832, RRID:AB_2565511) or eFluor450 anti-mouse CD45.2 antibody, clone 104 (eBioscience Cat# 48–0454-82, RRID: AB_11042125) PE anti-mouse CD11b antibody, clone M1/M7 (eBiosciences Cat# 12–0112-82, RRID: AB_2734869) PE anti-mouse Gr1/Ly-6G antibody, clone RB6–8C5 (eBioscience Cat# 12–5931-82, RRID: AB_466045) APC anti-mouse CD4 antibody, clone RM4–5 (eBioscience Cat# 17–0042-83; RRID:AB_469324) APC anti-mouse CD8 antibody, clone 53–6.7 (eBioscience 17–0081-83.

Techniques: Staining